Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Summary

The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).

Timeline

Start

2022-10-20

Primary completion

2024-10-19

Completion

2026-10-19

Drugs

Indications